Guggenheim Raises Price Target for Assembly Biosciences to $39 on Strong Clinical Data

Investment firm Guggenheim has issued a bullish update on Assembly Biosciences, increasing its price target for the biopharmaceutical company to $39 per share. This optimistic reassessment follows the release of compelling interim data from a Phase 1b clinical trial for the company’s investigational herpes treatment, ABI-5366.

The analyst’s research note highlighted particularly strong results from the study. The drug candidate demonstrated a remarkable 94 percent reduction in HSV-2 viral load, accompanied by a corresponding decline in genital lesions. These outcomes significantly surpassed the trial’s predefined objectives, indicating substantial therapeutic potential.

This latest clinical success builds upon a series of positive developments for Assembly Biosciences in recent weeks. The company’s second-quarter financial performance exceeded analyst forecasts, with a reported loss per share of $1.33, notably better Read more...